Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HLVX NASDAQ:NRSN NASDAQ:SAVA NASDAQ:TCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHLVXHilleVax$2.11-0.9%$1.95$1.34▼$2.17$105.70M0.76302,284 shs1,242 shsNRSNNeuroSense Therapeutics$2.00+1.1%$1.82$0.51▼$2.60$27.27M1.66258,772 shs34,937 shsSAVACassava Sciences$2.08+0.7%$2.02$1.15▼$42.20$100.24M-2.041.53 million shs83,958 shsTCRXTScan Therapeutics$1.82+2.5%$1.51$1.02▼$7.89$101.58M0.97409,329 shs25,176 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHLVXHilleVax-1.84%+3.90%+15.14%+29.09%+21.71%NRSNNeuroSense Therapeutics-1.00%-5.71%-16.81%+92.05%+114.26%SAVACassava Sciences-4.63%-0.96%+0.49%+47.14%-83.29%TCRXTScan Therapeutics-7.81%+4.12%+14.19%+36.15%-75.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHLVXHilleVax2.0682 of 5 stars1.05.00.00.03.03.31.3NRSNNeuroSense Therapeutics2.4624 of 5 stars3.54.00.00.01.91.70.0SAVACassava Sciences4.2711 of 5 stars3.33.00.04.72.70.81.3TCRXTScan Therapeutics3.5536 of 5 stars3.55.00.00.02.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHLVXHilleVax 2.00Hold$2.00-4.94% DownsideNRSNNeuroSense Therapeutics 3.00Buy$14.00601.75% UpsideSAVACassava Sciences 2.50Moderate Buy$54.502,525.24% UpsideTCRXTScan Therapeutics 3.00Buy$7.80329.52% UpsideCurrent Analyst Ratings BreakdownLatest NRSN, HLVX, TCRX, and SAVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.005/7/2025TCRXTScan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $10.005/6/2025TCRXTScan TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ATCRXTScan Therapeutics$2.82M36.44N/AN/A$4.26 per share0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHLVXHilleVax-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)NRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/A-445.40%N/ASAVACassava Sciences-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)TCRXTScan Therapeutics-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)Latest NRSN, HLVX, TCRX, and SAVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025TCRXTScan Therapeutics-$0.28N/AN/AN/AN/AN/A5/12/2025Q1 2025TCRXTScan Therapeutics-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/A5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHLVXHilleVaxN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ATCRXTScan TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHLVXHilleVaxN/A25.3225.32NRSNNeuroSense TherapeuticsN/A2.212.21SAVACassava SciencesN/A9.089.08TCRXTScan Therapeutics0.158.558.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHLVXHilleVax86.42%NRSNNeuroSense Therapeutics1.04%SAVACassava Sciences38.05%TCRXTScan Therapeutics82.83%Insider OwnershipCompanyInsider OwnershipHLVXHilleVax24.90%NRSNNeuroSense Therapeutics27.40%SAVACassava Sciences12.20%TCRXTScan Therapeutics4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableSAVACassava Sciences3048.31 million42.41 millionOptionableTCRXTScan Therapeutics10056.59 million54.13 millionNot OptionableNRSN, HLVX, TCRX, and SAVA HeadlinesRecent News About These CompaniesWall Street Zen Upgrades TScan Therapeutics (NASDAQ:TCRX) to HoldJuly 14 at 2:23 AM | americanbankingnews.comTScan Therapeutics (NASDAQ:TCRX) Rating Increased to Hold at Wall Street ZenJuly 12, 2025 | marketbeat.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 9, 2025 | marketbeat.comTscan Therapeutics Inc News (TCRX) - Investing.comJuly 9, 2025 | investing.comTScan Therapeutics (NASDAQ:TCRX) Stock Price Down 4% - Time to Sell?July 8, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comLynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockMay 22, 2025 | insidertrades.comWhat Analysts Are Saying About TScan Therapeutics StockMay 9, 2025 | nasdaq.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comTScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual MeetingApril 30, 2025 | nasdaq.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual MeetingApril 28, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%April 17, 2025 | aaii.comANeedham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)April 9, 2025 | markets.businessinsider.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%April 8, 2025 | aaii.comATScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTScan Therapeutics appoints Camiolo as SVP, Market AccessMarch 27, 2025 | markets.businessinsider.comTScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market AccessMarch 27, 2025 | globenewswire.comWhy TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 10.92%March 18, 2025 | aaii.comATScan Therapeutics assumed with an Overweight at Morgan StanleyMarch 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRSN, HLVX, TCRX, and SAVA Company DescriptionsHilleVax NASDAQ:HLVX$2.11 -0.02 (-0.94%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.NeuroSense Therapeutics NASDAQ:NRSN$2.00 +0.02 (+1.11%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Cassava Sciences NASDAQ:SAVA$2.08 +0.02 (+0.73%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.TScan Therapeutics NASDAQ:TCRX$1.82 +0.05 (+2.54%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
